2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Tuesday, November 10, 2015

4:30PM-6:00PM: Abstract Number: 3175

Strength at the Lumbar Spine and Hip Improves with Romosozumab Compared with Teriparatide in Postmenopausal Women with Low Bone Mass

Osteoporosis and Metabolic Bone Disease - Clinical Aspects and Pathogenesis

4:30PM-6:00PM: Abstract Number: 3159

Systemic Lupus Erythematosus Is a Risk Factor for Young Stroke: A Population-Based Cohort Study

Epidemiology and Public Health IV: Risk Factors and Comorbidities for SLE and Psoriatic Arthritis

4:30PM-6:00PM: Abstract Number: 3216

T Cell Restricted Deletion of Serine/Arginine-Rich Splicing Factor 1 (SRSF1) in Mice Causes Immune Cell Dysfunction and Contributes to Lupus-like Nephritis

Systemic Lupus Erythematosus - Animal Models

4:30PM-6:00PM: Abstract Number: 3183

The Clinical and Economic Costs of Not Achieving Remission in Rheumatoid Arthritis

Rheumatoid Arthritis - Clinical Aspects V: Goal = Remission

4:30PM-6:00PM: Abstract Number: 3203

The Clinical Efficacy and Safety of Baminercept, a Lymphotoxin-Beta Receptor Fusion Protein, in Primary Sjögren’s Syndrome: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Trial

Sjögren's Syndrome II: Clinical Discoveries

4:30PM-6:00PM: Abstract Number: 3232

The Comparative Efficacy of Kinesio Taping and Local Steroid Injection in Patients with Subacromial Impingement Syndrome

ARHP IV: Clinical Practice and Patient Care

4:30PM-6:00PM: Abstract Number: 3152

The IL-21 Signaling Pathway Is Enhanced in RA B Cells and Has the Potential to Alter Development and Cytokine Production in RA B Cells

B cell Biology and Targets in Autoimmune Disease: Novel B cell roles in RA and SLE

4:30PM-6:00PM: Abstract Number: 3154

The Importance of Somatic Hypermutation for the Immunoreactivity Towards Neutrophil Extracellular Traps (NETs)-Citrullinated Autoantigens of RA Synovial Monoclonal Antibodies

B cell Biology and Targets in Autoimmune Disease: Novel B cell roles in RA and SLE

4:30PM-6:00PM: Abstract Number: 3163

The Smoking Paradox in the Development of Psoriatic Arthritis Among Psoriasis Patients

Epidemiology and Public Health IV: Risk Factors and Comorbidities for SLE and Psoriatic Arthritis

4:30PM-6:00PM: Abstract Number: 1L

Tocilizumab for the Treatment of Giant Cell Arteritis – a Randomized Placebo-Controlled Trial

ACR Late-breaking Abstract Session

4:30PM-6:00PM: Abstract Number: 3178

Tocilizumab in Refractory Uveitis Associated to Juvenile Idiopathic Arthritis. Multicenter Study of 13 Cases

Pediatric Rheumatology - Clinical and Therapeutic Aspects IV: Imaging and Novel Clinical Interventions

4:30PM-6:00PM: Abstract Number: 5L

Tofacitinib in Patients with Ankylosing Spondylitis: A Phase 2, 16-Week, Randomized, Placebo-Controlled, Dose-Ranging Study

ACR Late-breaking Abstract Session

4:30PM-6:00PM: Abstract Number: 3198

Treatment of Rheumatoid Arthritis with an Anti-Tumor Necrosis Factor Agent or Tocilizumab As First Biologic Therapy in a Global Comparative Observational Study

Rheumatoid Arthritis-Small Molecules, Biologics and Gene Therapy VI: Strategies

4:30PM-6:00PM: Abstract Number: 3205

Treatment with Abatacept or Rituximab Targets T Follicular Helper Cells in Patients with Primary Sjogren s Syndrome

Sjögren's Syndrome II: Clinical Discoveries

4:30PM-6:00PM: Abstract Number: 3229

Using Exome Sequencing to Identify Novel Genetic Associations with Granulomatosis with Polyangiitis Susceptibility

Vasculitis IV

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].